The TWEAK receptor Fn14 is a therapeutic target in melanoma: Immunotoxins targeting Fn14 receptor for malignant melanoma treatment

Journal of Investigative Dermatology

Volumn 133, Issue 4, 2013, Pages 1052-1062

  Zhou, Hong ^a   Ekmekcioglu, Suhendan ^a   Marks, John W ^a   Mohamedali, Khalid A ^a   Asrani, Kaushal ^b   Phillips, Keeley K ^b   Brown, Sharron A N ^b   Cheng, Emily ^b   Weiss, Michele B ^c   Hittelman, Walter N ^a   Tran, Nhan L ^d   Yagita, Hideo ^e   Winkles, Jeffrey A ^b   Rosenblum, Michael G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^e JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL RECEPTOR; DIMER; FIBROBLAST GROWTH FACTOR INDUCIBLE PROTEIN 14; GELONIN; IMMUNOTOXIN; LIGAND; TUMOR NECROSIS FACTOR LIKE WEAK INDUCED OF APOPTOSIS RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; UPREGULATION; XENOGRAFT;

EID: 84875219244     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2012.402     Document Type: Article

References (37)

1. Als AB, Dyrskjot L, von der MH et al. (2007) Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res 13: 4407-14
2. Ascierto PA, Streicher HZ, Sznol M (2010) Melanoma: a model for testing new agents in combination therapies. J Transl Med 8:38
3. Balch CM, Gershenwald JE, Soong SJ et al. (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199-206
4. Brown SA, Ghosh A, Winkles JA (2010) Full-length, membrane-anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF-kappaB pathway. J Biol Chem 285:17432-41
5. Brown SA, Hanscom HN, Vu H et al. (2006) TWEAK binding to the Fn14 cysteine-rich domain depends on charged residues located in both the A1 and D2 modules. Biochem J 397:297-304
6. Burkly LC, Michaelson JS, Hahm K et al. (2007) TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine 40:1-16
7. Cao Y, Marks JD, Marks JW et al. (2009) Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies. Cancer Res 69:8987-95
8. Carrillo RJ, Dragan AI, Privalov PL (2010) Stability and DNA-binding ability of the bZIP dimers formed by the ATF-2 and c-Jun transcription factors. J Mol Biol 396:431-40
9. Clark WH Jr., Elder DE, Guerry D et al. (1984) A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 15:1147-65
10. Culp PA, Choi D, Zhang Y et al. (2010) Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanisms. Clin Cancer Res 16:497-508
11. Curtin JA, Fridlyand J, Kageshita T et al. (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135-47
12. Davies H, Bignell GR, Cox C et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-54
13. Do TN, Rosal RV, Drew L et al. (2003) Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site. Oncogene 22:1431-44
14. Flaherty KT, Yasothan U, Kirkpatrick P (2011) Vemurafenib. Nat Rev Drug Discov 10:811-2
15. Hale ML (2001) Microtiter-based assay for evaluating the biological activity of ribosome-inactivating proteins. Pharmacol Toxicol 88:255-60
16. Hocker TL, Singh MK, Tsao H (2008) Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. J Invest Dermatol 128:2575-95
17. Huang M, Narita S, Tsuchiya N et al. (2011) Overexpression of Fn14 promotes androgen-independent prostate cancer progression through MMP-9 and correlates with poor treatment outcome. Carcinogenesis 32:1589-96
18. Kroemer G, Martin SJ (2005) Caspase-independent cell death. Nat Med 11:725-30
19. Kwon OH, Park SJ, Kang TW et al. (2012) Elevated fibroblast growth factorinducible 14 expression promotes gastric cancer growth via nuclear factor-kappaB and is associated with poor patient outcome. Cancer Lett 314:73-81
20. Michaelson JS, Amatucci A, Kelly R et al. (2011) Development of an Fn14 agonistic antibody as an anti-tumor agent. MAbs 3:362-75
21. Michaelson JS, Burkly LC (2009) Therapeutic targeting of TWEAK/Fnl4 in cancer: exploiting the intrinsic tumor cell killing capacity of the pathway. Results Probl Cell Differ 49:145-60
22. Murray LJ, Abrams TJ, Long KR et al. (2003) SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20:757-66
23. Nakayama M, Ishidoh K, Kojima Y et al. (2003) Fibroblast growth factorinducible 14 mediates multiple pathways of TWEAK-induced cell death. J Immunol 170:341-8
24. Nazarian RM, Prieto VG, Elder DE et al. (2010) Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study. J Cutan Pathol 37(Suppl 1):41-7
25. Rosenblum MG, Kohr WA, Beattie KL et al. (1995) Amino acid sequence analysis, gene construction, cloning, and expression of gelonin, a toxin derived from Gelonium multiflorum. J Interferon Cytokine Res 15:547-55
26. Soengas MS, Lowe SW (2003) Apoptosis and melanoma chemoresistance. Oncogene 22:3138-51
27. Sondak VK, Smalley KS, Kudchadkar R et al. (2011) Ipilimumab. Nat Rev Drug Discov 10:411-2
28. Tran NL, McDonough WS, Donohue PJ et al. (2003) The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. Am J Pathol 162:1313-21
29. Tran NL, McDonough WS, Savitch BA et al. (2006) Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-kappaB and correlate with poor patient outcome. Cancer Res 66:9535-42
30. Tsao H, Atkins MB, Sober AJ (2004) Management of cutaneous melanoma. N Engl J Med 351:998-1012
31. Wang S, Zhan M, Yin J et al. (2006) Transcriptional profiling suggests that Barrett's metaplasia is an early intermediate stage in esophageal adenocarcinogenesis. Oncogene 25:3346-56
32. Watts GS, Tran NL, Berens ME et al. (2007) Identification of Fn14/TWEAK receptor as a potential therapeutic target in esophageal adenocarcinoma. Int J Cancer 121:2132-9
33. Whitlow M, Bell BA, Feng SL et al. (1993) An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. Protein Eng 6:989-95
34. Willis AL, Tran NL, Chatigny JM et al. (2008) The fibroblast growth factorinducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity. Mol Cancer Res 6: 725-34
35. Winkles JA (2008) The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 7:411-25
36. Zalevsky J, Chamberlain AK, Horton HM et al. (2010) Enhanced antibody halflife improves in vivo activity. Nat Biotechnol 28:157-9
37. Zhou H, Marks JW, Hittelman WN et al. (2011) Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells. Mol Cancer Ther 10:1276-88